NCT00099333 - Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide

Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.

DRUG

Insulin

Insulin will be taken according to the subject's current regimen

Trial Locations (5)

Research Site, Chula Vista

Research Site, Butte

Research Site, Portland

Research Site, Nashville

Research Site, San Antonio